Brokerages Set Catalent, Inc. (NYSE:CTLT) Price Target at $59.83

Shares of Catalent, Inc. (NYSE:CTLT - Get Free Report) have earned an average rating of "Hold" from the eight research firms that are covering the firm, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a hold rating. The average 1-year price objective among analysts that have covered the stock in the last year is $59.83.

A number of brokerages recently issued reports on CTLT. William Blair reiterated a "market perform" rating on shares of Catalent in a report on Tuesday, September 3rd. Royal Bank of Canada reiterated a "sector perform" rating and set a $63.50 price target on shares of Catalent in a report on Thursday, July 11th. Robert W. Baird restated a "neutral" rating and issued a $63.50 price objective on shares of Catalent in a report on Tuesday, September 24th. Baird R W downgraded Catalent from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 24th. Finally, StockNews.com lowered Catalent from a "hold" rating to a "sell" rating in a research report on Wednesday.

Catalent Stock Performance

Shares of CTLT stock traded down $0.06 on Thursday, reaching $59.89. The company had a trading volume of 2,188,452 shares, compared to its average volume of 2,049,834. The business's 50-day moving average is $60.03 and its 200 day moving average is $58.03. Catalent has a one year low of $32.38 and a one year high of $61.20. The company has a quick ratio of 1.96, a current ratio of 2.52 and a debt-to-equity ratio of 1.35.

Catalent (NYSE:CTLT - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same period in the previous year, the company earned ($0.10) EPS. Catalent's revenue for the quarter was up 4.2% on a year-over-year basis. Equities analysts predict that Catalent will post 0.95 EPS for the current year.

Insider Buying and Selling

In other Catalent news, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the sale, the insider now directly owns 36,304 shares in the company, valued at approximately $2,177,150.88. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.31% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Catalent

Large investors have recently bought and sold shares of the stock. Gamco Investors INC. ET AL grew its holdings in shares of Catalent by 403.3% in the first quarter. Gamco Investors INC. ET AL now owns 25,300 shares of the company's stock valued at $1,428,000 after acquiring an additional 20,273 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in Catalent by 2,792.9% in the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 516,390 shares of the company's stock valued at $29,150,000 after purchasing an additional 498,540 shares during the period. UniSuper Management Pty Ltd increased its position in shares of Catalent by 509.4% during the 1st quarter. UniSuper Management Pty Ltd now owns 18,204 shares of the company's stock valued at $1,028,000 after purchasing an additional 15,217 shares during the last quarter. Swedbank AB bought a new stake in shares of Catalent during the 1st quarter worth $1,659,000. Finally, SG Americas Securities LLC boosted its holdings in shares of Catalent by 147.4% in the 1st quarter. SG Americas Securities LLC now owns 99,588 shares of the company's stock worth $5,622,000 after buying an additional 59,339 shares during the last quarter.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.